Best case is around USD $43B.
So that's $141.38 x 43 / 4 = AUD $1519.
( $141.38 is the result for a USD $21B transaction, so above is the simple extrapolation to go from USD $4B to USD $43B revenue at 5.25x revenue multiple )
I just think a transaction much above the current ceiling is optimistic.
So maybe the transaction ceiling will lift from USD $21B to perhaps USD $30B.
The Juno Therapeutics buyout was on a 3x revenue multiple.
USD $9B buyout based on USD $3B revenue forecast.
https://www.fiercebiotech.com/biotech/celgene-confirms-9bn-juno-buyout-sees-3bn-sales-for-jcar017
The RAC 3-Pillar Trifecta, page-15
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.065(4.05%) |
Mkt cap ! $262.4M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.62 | $1.51 | $261.3K | 168.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 15.59pm 09/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |